Start
Features
Free trial / FAQ

Researchers
Physicians
Pharmacists
Ecotrophologists
Product Managers
in Health Industries

Loading…

Medical Research Finder

Legal Notice
Privacy
Terms of Use

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

meRfi® AI Chat

Bacillus subtilis + Bifidobacterium bifidum + Bifidobacterium longum + Lacticaseibacillus paracasei + Lactiplantibacillus plantarum + Leuconostoc mesenteroides + Limosilactobacillus reuteri + Pediococcus acidilactici & Type 2 diabetes (T2D)

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

(Login)

Navigation

Clinical data

ISRCTN48974890
revealed that Bacillus subtilis DE111 + Bifidobacterium bifidum + Bifidobacterium longum + Lacticaseibacillus paracasei + Lactiplantibacillus plantarum TBC0036 + Leuconostoc mesenteroides TBC0037 + Limosilactobacillus reuteri + Pediococcus acidilactici has the potential to restore balance in the gut, reduce inflammation, and enhance metabolic health in individuals with Type 2 Diabetes. It is suggested that further research is necessary to investigate its long-term effectiveness and wider use in managing metabolic diseases (1).

References

(1) García et al. 2024 Microorganisms 12(12): 2525

see also:
[Probiotics (living agents) & Type 2 Diabetes (T2D)](brain://nCQhJ3hV…

References (Sources)

Evaluating the effects of sugar shift® symbiotic on microbiome composition and LPS regulation: a double-blind, placebo-controlled study
García et al. 2024 Microorganisms 12(12): 2525

AI Chat

7/1/2026

Chat with our artificial intelligence:

Start chat!